A new partnership has developed that has seen Therapeutics, Inc. (Resilience) and PGI Drug Discovery LLC (PsychoGenics) and aims to research and develop new ways to treat Post-Traumatic Stress Disorder (PTSD) and related conditions. The partnership was agreed on March 2, 2015 and will see PGI Drug Discovery LLC a leader in phenotypic drug discovery making a calculated investment in Therapeutics, Inc. Through this partnership Therapeutics, Inc., will make technology platforms such as SmartCube® system available. It will also offer its expertise towards the development of new therapeutics for PTSD as well as other disorders that are stress-related.
PTSD is an unfortunate sickness that can occur after traumatic occurrences that in the U.S. alone affect well over eight million (NIH estimate). PTSD is even more unfortunate as it has commanded an astronomical sum of $3 billion yearly in healthcare cost and an even more mind-blowing $30 billion in indirect healthcare costs and socioeconomic losses.
Drug Discovery LLC is a pioneering leader in phenotypic drug discovery. The company uses its technology platforms by combining forces, with biotechnology and pharmaceutical companies. This is done to discover new and improved drugs, aimed at combating neuropsychiatric disorders. Additionally, the company offers a wide variety of in-licensed transgenic mouse models supporting research in other areas.
Started in 2014, Therapeutics, Inc. headquartered is in Boston, Massachusetts, with a lab in Cambridge, Massachusetts, mandate to discover a cure for PTSD. The company has an in-licensing program, described as neurobiological targets, which mark each significant pre-clinical development from various labs across the U.S. These labs in turn have their own set of programs dedicated to researching and studying the methodology entailing the susceptibility and resiliency after stress and trauma. The aim of these programs is to target the biological makeup of PTSD etiology thus allowing Therapeutics, Inc., to new, game changing and disease-modifying therapeutics to those affected.